Background The treatment of KRAS G12C-mutant non-small cell lung cancer (NSCLC) has become a dominant field of ongoing translational research. Still, the effect of the first KRAS G12C inhibitor, sotorasib, or next-generation inhibitors, such as fulzerasib, in KRAS-mutant NSCLC patients is short-lived. Although the obje...
A. Giménez-Capitán, D. Olmo-González, E. Martínez-Pérez et al.· Annals of Translational Medi...· 0 citations
Findings support nilotinib as a promising therapeutic candidate for KRAS-mutant NSCLC after a structure-based drug repurposing approach was employed to screen FDA-approved compounds targeting key regulators to the MAPK signalling pathway.
Anisha Jain, Chandan Dharmashekar, B. S et al.· Scientific Reports· 0 citations
These findings provide a preliminary mechanistic and experimental framework for DCA as a dietary FTO inhibitor in breast cancer, necessitating further validation through orthogonal target engagement assays, m6A quantification, and in vivo tumor models.
Shuaib Pasha, S. Harishkumar, Revanth Handralu Chandraiah et al.· Naunyn-Schmiedeberg's Archiv...· 0 citations
In the H2030 xenograft model, tumor growth was significantly inhibited by treatment with the three-drug combination of omeprazole, sotorasib, and selinexor, with no apparent toxic side-effects or weight loss observed.